Clopidogrel does not benefit infants with congenital heart disease

06/19/2013 | DoctorsLounge.com

Clopidogrel therapy did not yield better outcomes for babies with cyanotic congenital heart disease and a systemic-to-pulmonary-artery shunt compared with placebo and conventional treatment, a study showed. Rates of death, overall bleeding and severe bleeding were similar for both clopidogel and placebo groups, researchers reported in the New England Journal of Medicine.

View Full Article in:

DoctorsLounge.com

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA
Food Lawyer
Cargill
Wayzata, MN
Director of Clinical Research
Regenesis Biomedical, Inc.
Scottsdale, AZ
Actuary
Meridian Health Plan
Detroit, MI
Assistant Vice President - Dental Director
MetLife
Bridgewater, NJ